Cargando…

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2– advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jerzak, Katarzyna J., Bouganim, Nathaniel, Brezden-Masley, Christine, Edwards, Scott, Gelmon, Karen, Henning, Jan-Willem, Hilton, John F., Sehdev, Sandeep
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297170/ https://www.ncbi.nlm.nih.gov/pubmed/37366894 http://dx.doi.org/10.3390/curroncol30060411

Ejemplares similares

Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”
por: Rayson, Daniel, et al.
Publicado: (2023)

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
por: Rayson, Daniel, et al.
Publicado: (2022)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
por: Ferrario, Cristiano, et al.
Publicado: (2022)

A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer
por: Brezden-Masley, Christine, et al.
Publicado: (2020)

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

A population‐based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with triple‐negative breast cancer
por: Brezden‐Masley, Christine, et al.
Publicado: (2020)

Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2017)

Redefining Heart Failure in Breast Cancer
por: Volgman, Annabelle Santos, et al.
Publicado: (2022)

Cancer and Cardiovascular Disease: The Complex Labyrinth
por: Dent, Susan, et al.
Publicado: (2015)

Lgr5 and stem/progenitor gene expression in gastric/gastroesophageal junction carcinoma – significance of potentially retained stemness
por: Yoon, Ju-Yoon, et al.
Publicado: (2020)

Autophagic Heterogeneity in Gastric Adenocarcinoma
por: Yoon, Ju-Yoon, et al.
Publicado: (2021)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
por: Wilson, Florence R., et al.
Publicado: (2018)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Intestinal Metaplasia and the Risk of Gastric Cancer in an Immigrant Asian Population
por: Abadir, Amir, et al.
Publicado: (2012)

Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study
por: Yoon, Ju-Yoon, et al.
Publicado: (2019)

Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer
por: Simmons, Christine E., et al.
Publicado: (2020)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2− Metastatic Breast Cancer
por: Song, Yan, et al.
Publicado: (2015)

Mammographic microcalcifications and breast cancer tumorigenesis: a radiologic-pathologic analysis
por: Naseem, Madiha, et al.
Publicado: (2015)

Effect of HER2 expression status on the prognosis of patients with HR(+)/HER2(‑) advanced breast cancer undergoing advanced first‑line endocrine therapy
por: Wang, Kan, et al.
Publicado: (2023)

SYST-05 OPTIMIZING HER2-TARGETED THERAPIES (TT) FOR BREAST CANCER (BC) LEPTOMENINGEAL METASTASES (LM): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Lazaratos, Anna-Maria, et al.
Publicado: (2022)

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison
por: Rugo, Hope S., et al.
Publicado: (2023)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study
por: Sue-Chue-Lam, Colin, et al.
Publicado: (2023)

HER2-LOW BREAST CANCER BRAIN METASTASES: INCIDENCE AND TREATMENT IMPLICATIONS
por: Chehade, Rania, et al.
Publicado: (2023)

Clinicians’ Perspectives on Barriers to Discussing Infertility and Fertility Preservation With Young Women With Cancer
por: Covelli, Andrea, et al.
Publicado: (2019)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting
por: Dawood, Shaheenah, et al.
Publicado: (2021)

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain
por: Galve-Calvo, Elena, et al.
Publicado: (2018)

HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
por: Stellato, Daniel, et al.
Publicado: (2021)

American Society of Clinical Oncology 2021 Podcast: HR+, HER2− Breast Cancer
por: Cheung, Kwok-Leung
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

CERN HR receives award for on-line recruitment and communication
por: Joannah Caborn Wengler
Publicado: (2012)

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
por: Forsythe, Anna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mce2lhq6honk7s3pidruvr10nv